Longeveron (LGVN) Free Cash Flow Growth (1y) (2021 - 2026)
Longeveron (LGVN) Free Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1,092.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 66.37% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 3.98% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Longeveron | 14.87 Bn | 14.86 Bn | 264,000.00 | 7.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.49% |
| Dec 31, 2025 | -56.41% |
| Sep 30, 2025 | -56.19% |
| Jun 30, 2025 | 21.08% |
| Mar 31, 2025 | -52.29% |
| Dec 31, 2024 | 18.63% |
| Sep 30, 2024 | 28.21% |
| Jun 30, 2024 | -1.47% |
| Mar 31, 2024 | 47.33% |
| Dec 31, 2023 | -75.27% |
| Sep 30, 2023 | 1.15% |
| Jun 30, 2023 | -39.96% |
| Mar 31, 2023 | -40.27% |
| Dec 31, 2022 | -49.03% |
| Sep 30, 2022 | -94.52% |
| Jun 30, 2022 | -13.58% |
| Mar 31, 2022 | -38.49% |
| Dec 31, 2021 | -223.78% |
| Sep 30, 2021 | -863.82% |
| Jun 30, 2021 | -140.20% |